MORARI, Michele
 Distribuzione geografica
Continente #
NA - Nord America 8.854
EU - Europa 2.062
AS - Asia 1.244
OC - Oceania 6
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.174
Nazione #
US - Stati Uniti d'America 8.832
CN - Cina 823
UA - Ucraina 586
IT - Italia 408
TR - Turchia 373
DE - Germania 335
GB - Regno Unito 274
SE - Svezia 148
FI - Finlandia 136
PL - Polonia 41
BE - Belgio 39
AT - Austria 38
FR - Francia 38
CA - Canada 20
IN - India 11
IR - Iran 10
VN - Vietnam 8
HK - Hong Kong 6
AU - Australia 5
NL - Olanda 5
JP - Giappone 4
RO - Romania 4
BR - Brasile 3
RU - Federazione Russa 3
SG - Singapore 3
EU - Europa 2
IE - Irlanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BD - Bangladesh 1
BG - Bulgaria 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
EC - Ecuador 1
ES - Italia 1
IQ - Iraq 1
KH - Cambogia 1
KR - Corea 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
TW - Taiwan 1
Totale 12.174
Città #
Fairfield 1.266
Woodbridge 1.234
Houston 683
Ashburn 670
Jacksonville 670
Chandler 666
Ann Arbor 517
Seattle 472
Wilmington 450
Cambridge 415
Izmir 236
Beijing 227
Nanjing 173
Princeton 165
Ferrara 158
San Diego 114
Boardman 103
Shanghai 87
Milan 75
Bremen 65
Shenyang 57
New York 56
Falls Church 48
Hebei 45
Warsaw 41
Brussels 38
Nanchang 38
Vienna 38
Tianjin 35
Changsha 29
Norwalk 29
Jiaxing 28
San Mateo 25
Auburn Hills 24
Washington 24
Jinan 22
Mountain View 21
Munich 21
Redwood City 20
Los Angeles 18
Dearborn 17
London 17
Zhengzhou 15
Orange 14
Leawood 13
Mcallen 13
Montréal 12
Addison 11
Guangzhou 11
Lappeenranta 11
Redmond 11
Tappahannock 11
Kunming 10
Verona 10
Des Moines 9
Dong Ket 8
Helsinki 8
Indiana 8
Ningbo 8
Taizhou 8
Augusta 7
Morciano Di Romagna 7
Ardabil 6
Changchun 6
Hong Kong 6
Monterenzio 6
Fuzhou 5
Chicago 4
Cordignano 4
Hangzhou 4
Ottawa 4
Philadelphia 4
Rome 4
Walnut 4
Ferrara di Monte Baldo 3
Frankfurt am Main 3
Kilburn 3
Lanzhou 3
Marsala 3
Mumbai 3
Napoli 3
Prescot 3
San Francisco 3
Serra 3
Singapore 3
Acton 2
Altavilla Vicentina 2
Amsterdam 2
Aurora 2
Bangalore 2
Bologna 2
Brindisi 2
Casalecchio di Reno 2
Chiswick 2
Delianuova 2
Düsseldorf 2
Haikou 2
Hefei 2
Hounslow 2
Melbourne 2
Totale 9.462
Nome #
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 189
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 159
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 155
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 146
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 144
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 140
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 134
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 132
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 126
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 123
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 123
Loss of cortical GABA terminals in Unverricht–Lundborg disease 123
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 123
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 123
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 122
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 120
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 119
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 119
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 118
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias 118
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 118
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 116
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 115
Role of LRRK2 in the regulation of dopamine receptor trafficking 115
5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea-pig cortical slices. 115
null 113
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 113
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 112
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 112
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 111
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 110
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 110
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs. 109
null 108
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 108
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 108
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices. 107
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 107
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 106
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 106
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 106
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. 106
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 105
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 103
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 103
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 103
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 102
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. 101
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 101
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 101
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 100
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 100
Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. 99
Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release 99
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 98
Antagonisti dei recettori NOP e loro usi terapeutici 97
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats 97
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 97
Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata: A microdialysis study in the awake freely moving rat. 94
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 94
null 94
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 93
null 92
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 92
null 92
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 92
null 91
Parkinson's disease: no NOP, new hope 90
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 90
null 89
null 88
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 88
null 87
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat. 87
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 87
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum 87
null 87
null 84
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 84
null 82
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 82
Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin 81
Synthesis and structure activity relationships of delthorphine analogues 80
Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult Rats 80
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance. 78
NOP receptor ligands and Parkinson’s disease 78
null 77
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 77
Autophagy and LRRK2 in the Aging Brain 77
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 75
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 75
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 74
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 73
L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: Modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors 73
Agonisti dei recettori NOP per il trattamento delle discinesie da levodopa; 72
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 72
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 70
null 69
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling 62
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 60
Totale 10.142
Categoria #
all - tutte 50.390
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.021
Totale 51.411


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019661 0 0 0 0 0 0 0 0 0 0 0 661
2019/20202.941 436 101 99 422 183 316 266 313 252 282 206 65
2020/20212.004 165 170 94 225 111 166 104 237 67 262 264 139
2021/20221.562 53 169 130 70 81 95 98 87 55 117 153 454
2022/20231.619 170 132 75 181 263 218 72 124 224 4 101 55
2023/2024638 84 103 39 23 76 135 34 63 24 19 9 29
Totale 12.379